«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:

期数:

2020年05期

页码:

597-601

栏目:

论著

出版日期:

2020-10-20

文章信息/Info

Title:

Short term and long term efficacy of radioactive iodine 125 seed implantation in the treatment of local non-small cell lung cancer

作者:

孙俊凯; 李书书; 陈 卫

214000 无锡,无锡市第五人民医院介入科

Author(s):

Sun Junkai;  Li Shushu;  Chen Wei.

Department of Intervention, Wuxi Fifth People's Hospital, Wuxi 214000, China

关键词:

碘125粒子;  非小细胞肺癌;  放疗;  恶性肿瘤

Keywords:

¹²⁵Iodine seeds;  Non-small cell lung cancer;  Radiotherapy;  Malignant tumor

分类号:

R734.2

DOI:

10.3877/cma.j.issn.1674-6902.2020.05.004

摘要:

目的 探讨放射性碘125(¹²⁵I)粒子植入治疗局部非小细胞肺癌(NSCLC)的近远期疗效。方法 选择2015年1月到2018年1月无锡市第五人民医院收治的67例局部NSCLC患者作为研究对象,按照随机数字表法将其随机分为研究组32例和对照组35例,对照组采取紫杉醇联合顺铂静脉滴注方案进行化疗,研究组在对照组基础上采取放射性¹²⁵I粒子植入术治疗,比较两组临床疗效,比较两组治疗前后癌胚抗原(CEA)、细胞角质素片段抗原21-1(CYFRA21-1)、糖类抗原125(CA125)水平及癌症患者生活质量核心量表(EORTC QLQ-C30)评分,比较两组治疗期间不良反应发生情况及近远期随访生存情况。结果 研究组治疗后ORR为81.25%显著高于对照组57.14%,差异有统计学意义(P<0.05)。研究组治疗后CYFRA21-1、CA125显著低于治疗前及对照组治疗后(P<0.05); 两组治疗后CEA组内比较显著低于治疗前(P<0.05)。研究组治疗后躯体症状评分显著低于治疗前及对照组治疗后(P<0.05); 两组治疗后总体功能、总体健康评分显著高于治疗前(P<0.05)。研究组不良反应总发生率为53.13%,与对照组37.14%比较,差异无统计学意义(P>0.05)。研究组半年、1年、2年存活率分别为96.88%、87.50%、75.00%,显著高于对照组半年、1年、2年存活率82.86%、65.71%、48.57%,差异有统计学意义(Log-Rank=5.124,P=0.024)。结论 放射性¹²⁵I粒子植入治疗可显著提高局部NSCLC患者近远期生存率,改善患者体内血清肿瘤标志物水平,且安全性良好,临床价值较高。

Abstract:

Objective To study the short-term and long-term efficacy of radioactive iodine 125(¹²⁵I)seeds implantation in the treatment of local non-small cell lung cancer(NSCLC). Methods All 67 patients with local NSCLC admitted to the Fifth People's Hospital of Wuxi City from January 2015 to January 2018 were selected as the research objects and randomly divided into study group 32 cases and control group 35 cases according to random number table method; The control group was treated with paclitaxel combined with cisplatin for chemotherapy, while the observation group was treated with radioactive ¹²⁵I seed implantation on the basis of the control group, The clinical efficacy, CEA, CYFRA21-1, CA125 and EORTC QLQ-C30 scores were compared between the two groups before and after treatment, and the adverse reactions and The incidence of adverse reactions and short-term and long-term follow-up survival of the two groups were compared. Results The ORR of the study group was 81.25%, which was significantly higher than that of the control group(57.14%)(P<0.05). After treatment, CYFRA21-1 and CA125 in the study group were significantly lower than those before treatment and after treatment in the control group(P<0.05); the CEA levels in the two groups after treatment were significantly lower than those before treatment(P<0.05). The body symptom score of the study group after treatment was significantly lower than that before treatment and after treatment in the control group(P<0.05); the overall function and overall health score of the two groups after treatment were significantly higher than those before treatment(P<0.05). The total incidence of adverse reactions in the study group was 53.13%, compared with 37.14% in the control group, the difference was not statistically significant(P>0.05). The half year, one-year and two-year survival rates of the study group were 96.88%, 87.50% and 75.00%, which were significantly higher than those of the control group(82.86%, 65.71% and 48.57%)respectively, and the difference was statistically significant(Log-Rank=5.124, P=0.024). Conclusion Radioactive ¹²⁵I seed implantation therapy can significantly improve the short-term and long-term survival rate of patients with local NSCLC, improve the serum tumor markers level of patients, and has good safety and high clinical value.

参考文献/References:

1 Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated egfr-mutated advanced non-small-cell lung cancer[J]. New England Journal of Medicine, 2018, 378(2): 113-125.
2 庄胜跃, 李东文. 高龄Ⅰ期非小细胞肺癌患者综合治疗研究进展[J]. 临床军医杂志, 2018, 46(9): 124-125.
3 王淋丽, 李 娜, 廖玉芳, 等. 非小细胞肺癌一线化疗药物的研究进展[J]. 中国药房, 2016, 27(5): 717-720.
4 Kim YH, Mishima M. Consolidation chemotherapy after concurrent chemoradiotherapy in patients with stage Ⅲ non-small-cell lung cancer[J]. Journal of Clinical Oncology, 2016, 34(7): 767-767.
5 袁 鹏, 李文会, 岳天华, 等. 局部进展期非小细胞肺癌同步放化疗+放射性Ⅰ粒子植入治疗初步研究[J]. 中华放射肿瘤学杂志, 2019, 28(8): 584-587.
6 陆 舜, 虞永峰, 纪文翔. 2015年肺癌诊疗指南:共识和争议[J]. 解放军医学杂志, 2016, 41(1): 1-6.
7 叶 波, 赵 珩. 第八版国际肺癌TNM分期修订稿解读[J]. 中国肺癌杂志, 2016, 19(6): 337-342.
8 梁秀婷, 吴 洁. ECOG评分量表在肺癌化疗患者分级护理中的应用[J]. 解放军预防医学杂志, 2016, 34(4): 125-125.
9 丁 婕, 戴 旭, 孟宪运, 等. 实体瘤疗效评价标准的研究进展[J]. 中国肿瘤临床与康复, 2015, 22(9): 1150-1152.
10 王 岩, 朱 琳, 陈 鹏. 肿瘤患者生命质量测定量表EORTC QLQ-C30维文版评价[J]. 中国卫生统计, 2015, 32(3): 146-147.
11 陈亚平, 姜晓晓, 冯守信, 等. 老年非小细胞肺癌立体定向体部放疗联合化疗的临床观察[J]. 中华肿瘤防治杂志, 2015, 22(22): 1779-1782.
12 李 硕, 马 武. ¹²⁵I放射性粒子组织间植入治疗中晚期恶性肿瘤的研究进展[J]. 现代肿瘤医学, 2018, 26(7): 1128-1131.
13 尤美芹, 王守华, 蒋从飞, 等. 放射性¹²⁵I粒子植入治疗放化疗后进展晚期恶性肿瘤患者的临床分析[J]. 中国肿瘤临床与康复, 2018, 25(8): 992-994.
14 Quivey JM, Augsburger J, Snelling L, et al. ¹²⁵I plaque therapy for uveal melanoma. Analysis of the impact of time and dose factors on local control[J]. Cancer, 2015, 77(11): 2356-2362.
15 宋 勇, 杨 雯. 2014年晚期非小细胞肺癌内科治疗进展[J]. 解放军医学杂志, 2015, 40(1): 10-15.
16 Garon EB, Rizvi NA, Hui R, et al. Supplementary Pembrolizumab for the treatment of non-small-cell lung cancer[J]. New England Journal of Medicine, 2015, 372(21): 2018-2028.
17 王宝强, 周陈华. 紫杉醇联合顺铂同步放化疗治疗局部晚期非小细胞肺癌的临床疗效及安全性评价[J]. 中国临床药理学杂志, 2015, 31(8): 603-605.
18 Breese CR, Adams C, Logel J, et al. Comparison of the regional expression of nicotinic acetylcholine receptor alpha7 mRNA and [¹²⁵I]-alpha-bungarotoxin binding in human postmortem brain[J]. Journal of Comparative Neurology, 2015, 387(3): 385-398.
19 何 枫, 郎伟思, 吴小明, 等. ¹²⁵I粒子植入联合化疗治疗原发性中晚期非小细胞肺癌的疗效观察[J]. 第三军医大学学报, 2017, 39(23): 2307-2311.
20 吕艳玲, 袁冬梅, 金淑贤, 等. 非小细胞肺癌患者癌胚抗原、C反应蛋白表达水平与预后的关系[J/CD]. 中华肺部疾病杂志(电子版), 2016, 9(2): 140-144.
21 汤山松. 血清CYFRA21-1和CEA联合检测诊断非小细胞肺癌的临床研究[J]. 热带医学杂志, 2017, 17(12): 1626-1628.
22 陆 健, 刘 琳, 陈志瑾, 等. 进展期非小细胞肺癌¹²⁵I粒子植入前后CEA、CYFRA21-1变化与临床疗效评估[J]. 介入放射学杂志, 2016, 25(3): 234-238.
23 李小东, 张遵城, 郑广钧, 等. ¹²⁵I粒子植入治疗非小细胞肺癌的剂量学优化研究[J]. 中华核医学与分子影像杂志, 2015, 35(1): 36-40.
24 何伟娜, 庞 敏, 张卫华, 等. ¹²⁵I粒子植入联合微波消融术对中晚期非小细胞肺癌的近期疗效[J]. 中国临床研究, 2020, 33(2): 180-182.
25 代国军, 金志良. 中医益气养阴法对三维适行放疗局部晚期非小细胞肺癌老年患者生活质量及免疫功能的影响[J]. 现代中西医结合杂志, 2017, 26(15): 72-75.
26 杜 鹏, 卢 伟, 肖越勇, 等. 改良¹²⁵I粒子植入技术治疗肺功能不全肺癌的安全性和有效性[J]. 中华放射学杂志, 2016, 50(1): 32-36.
27 曹德东, 尹竺晟, 戈 伟. ¹²⁵I粒子植入放射治疗联合含铂化疗方案治疗晚期非小细胞肺癌疗效及安全性的Meta分析[J]. 中国医药导报, 2017, 14(2): 97-101.
28 Cao J, Yuan P, Wang Y, et al. Survival Rates After Lobectomy, Segmentectomy and Wedge Resection for the Non-Small Cell Lung Cancer[J]. Annals of Thoracic Surgery, 2018, 105(5): 1483-1491.
29 邹佳丽, 陆 武, 陈 鹏, 等. CT引导¹²⁵I粒子植入联合化疗对不可切除非小细胞肺癌的疗效分析[J]. 中华核医学与分子影像杂志, 2019, 39(2): 96-99.
30 张友文, 王丽君, 曹艺巍, 等. 放射性¹²⁵I粒子植入治疗非小细胞肺癌的现状与进展[J]. 中国医师进修杂志, 2019, 42(7): 666-669.

备注/Memo

备注/Memo:

通信作者: 孙俊凯, Email: zhagg9898@126.com

常用功能

更新日期/Last Update: 2020-10-20